Studying the Targeted Therapy Olaparib Given with Radium-223 for Advanced Prostate Cancer with Bone Metastasis

About the Study

This study is measuring the best dosage for and side effects of the drug combination Olaparib and radium-223 to treat men with metastatic, castration-resistant prostate cancer that has spread to the bones. 

This study is no longer recruiting patients

Type of Study

This is a randomized study with two separate treatment groups.      

Participants are placed into one of two study groups by chance, and neither the participants nor the researchers choose the group into which the participants are placed.

• Group 1 participants will receive radium injection and oral olaparib.

• Group 2 participants will receive radium injection only.

The study allows crossover. Participants in Group 2 whose cancer gets worse will be allowed to switch to Group 1 and receive olaparib.

What the Study Involves

• The study involves up to 6 cycles of 28 days, for a total of 168 days. All participants will receive an injection of radium-223 into their vein, two times on day one, then again every 28 days.
  • Group 1 participants will also receive olaparib orally two times daily for the entire 168 day treatment period.      
  • Group 2 participants will not receive olaparib, unless their cancer gets worse. Participants in Group 2 whose cancer gets worse will be allowed to switch over to Group 1 to receive olaparib.       

• Participants will be followed for up to two years for side effects, quality of life, and progression of disease.

Study Sites

California

• San Diego, CA
  UC San Diego Moores Cancer Center Recruiting
  Contact: 858-822-5354 or by email: [email protected]  
  Lead researcher: Rana R. McKay, MD
• Sacramento, CA
  University of California Davis Comprehensive Cancer Center 
  Contact: 916-734-3089
  Lead researcher: Mamta Parikh, MD  

Kansas

• Fairway, KS
  University of Kansas Clinical Research Center    
  Contact: 913-588-3671 or by email: [email protected]
  Lead researcher: Rahul A. Parikh, MD
• Kansas City, KS         
  University of Kansas Cancer Center
  Contact: 913-588-3671 or by email: [email protected]
  Lead researcher: Rahul A. Parikh, MD 
• Overland Park, KS         
  University of Kansas Cancer Center
  Contact: 913-588-3671 or by email: [email protected]
  Lead researcher: Rahul A. Parikh, MD
• Westwood, KS         
  University of Kansas Hospital-Westwood Cancer Center 
  Contact: 913-588-3671 or by email: [email protected]
  Lead researcher: Rahul A. Parikh, MD

Maryland

• Baltimore, MD
  University of Maryland/Greenebaum Cancer Center             
  Contact: 800-888-8823
  Lead researcher: Arif Hussain, MD     

Missouri

• Creve Coeur, MO
  Siteman Cancer Center at West County Hospital
  Contact: 800-600-3606 or by email: [email protected]
  Lead researcher: Hiram A. Gay, MD   
• Kansas City, MO         
  University of Kansas Cancer Center - North
  Contact: 913-588-3671 or by email: [email protected]
  Lead researcher: Rahul A. Parikh, MD   
• Lee's Summit, MO         
  University of Kansas Cancer Center - North
  Contact: 913-588-3671 or by email: [email protected]
  Lead researcher: Rahul A. Parikh, MD
• Saint Louis, MO
  Washington University School of Medicine
  Contact: 800-600-3606 or by email: [email protected]
  Lead researcher: Hiram A. Gay, MD  
• Saint Louis, MO
  Siteman Cancer Center-South County 
  Contact: 800-600-3606 or by email: [email protected]
  Lead researcher: Hiram A. Gay, MD
• Saint Peters, MO
  Siteman Cancer Center at Saint Peters Hospital  
  Contact: 800-600-3606 or by email: [email protected]
  Lead researcher: Hiram A. Gay, MD 

New Jersey

• New Brunswick, NJ
  Rutgers Cancer Institute of New Jersey
  Contact: 732-235-7356
  Lead researcher: Biren Saraiya, MD    

Ohio

• Columbus, OH
  Ohio State University Comprehensive Cancer Center           
  Contact: 800-293-5066 or by email: [email protected]
  Lead researcher: Edmund Folefac, MD   

Pennsylvania

• Pittsburgh, PA
  University of Pittsburgh Cancer Institute (UPCI)       
  Contact: 412-647-8073     
  Lead researcher: Adam Olson, MD 

Wisconsin

• Madison, WI
  University of Wisconsin Carbone Cancer Center
  Contact: 800-622-8922     
  Lead researcher: Christos Kyriakopoulos